Gain insights from our experts...
Optimizing lipid nanoparticles (LNPs) processing for siRNA delivery by microfluidics system
The success of mRNA vaccines during the COVID-19 pandemic has accelerated the advancement of nucleic acid delivery technologies. In addition to mRNA, interfering RNA offers potential to treat diseases beyond the reach of small molecules. However, therapeutic success hinges on efficient and targeted delivery systems. Lipid nanoparticles (LNPs), especially those produced via microfluidics, have emerged as a leading platform for RNA delivery. delivery. for RNA.
Join Dr. Qiaobin Hu as he explores LNP formulation for siRNA delivery using a microfluidic flow-focusing system.
Optimising lipid nanoparticles (LNPs) processing for siRNA delivery by microfluidics system
866.3 KB
Explore our poster presentation with Qiaobin Hu
Explore additional content
recent insights:
A proven foundation: the history of aluminium adjuvants
Vaccine developers today have access to an expanding range of adjuvant technologies. However, aluminium-based adjuvants remain some of the most established and widely used ingredients for vaccine...
Formulation challenges in GLP-1 therapeutics: Why excipient purity matters
GLP-1-based peptide therapeutics are transforming the treatment of obesity and type 2 diabetes. As developers race to advance the next generation of these medicines, formulation scientists face a less...
One month countdown until CPHI Europe
In a month’s time, over 20 colleagues spanning sales, marketing, R&D and sustainability will be amongst the action at CPHI Europe 2026 in Milan – one of the most important events in the pharmaceutical...